Government-Owned Inventions; Availability for Licensing, 52804-52805 [E6-14831]
Download as PDF
<![CDATA[
52804
Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices
Dated: August 29, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–14753 Filed 9–6–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
rwilkins on PROD1PC63 with NOTICES
Oligo Microarray for Detection of All
Known Mammalian and Avian
Pathogenic Viruses
Description of Technology: The
spectrum of pathogenic viruses of
importance in human disease,
agriculture and biology is not only large
and diverse, but continually evolving.
The identification or isolation of viral
pathogens, in correlation with the
presence of specific disease phenotypes,
is of paramount importance both to
diagnosis of disease and the subsequent
management or treatment of viral
infection. The limitations of current
viral detection methods, such as PCR
and immunoassays, led to the
development of a novel microarray
system for specific detection of viruses.
The technology offered here for
licensing provides a method for highthroughput screening of known
pathogenic viruses along with
VerDate Aug<31>2005
18:11 Sep 06, 2006
Jkt 208001
identification of ‘‘new’’ diseaseassociated viruses.
The novel method is based on a viral
microarray containing 10,000
immobilized DNA oligonucleotide
features, representing all known
mammalian and avian pathogenic
viruses (approximately 600). Software
was also developed to analyze the viral
microarray results. The oligonucleotide
features in this system are 60-mer long
and distributed across both conserved
and non-conserved regions of known
viral sequences. This design serves the
dual purpose of: (1) Facilitating
validation via redundant signals
associated with each represented virus
and (2) allowing for the discovery of
new viruses, which arise due to
recombination. In addition, positive and
negative controls against human and
mouse housekeeping genes are included
along with software for analysis of virus
microarray results.
Further advantages of the viral
microarray include: (a) The use of
sample inputs as little as 10ng of either
total DNA or RNA extracted from virus
infected cells, representing as few as 20
viral particles; (b) detection of viruses of
both DNA and RNA classes; (c) a
capacity for high-throughput screening
of various sample types including
serum, saliva and biopsy tissues; and (d)
analysis of a large number of samples in
parallel on identical arrays.
The detection of viral DNA is unique
to this technology, as other available
technologies only detect viral genomic
RNA or viral mRNA transcripts.
Additionally, the viral chip was found
to be highly specific and sensitive for
detecting different viral genomic
sequences in cell lines and multiple
viral constructs co-infection in cultured
cells.
Applications: (1) Detection and
identification of viruses that cause
disease; (2) Efficient discovery of new
pathogenic viruses; (3) Diagnosis of
human and animal disease outbreaks;
(4) Identification of viral agents used in
bioterrorism.
Development Status: (1) The preclinical performance of the viral
microarray was evaluated by application
of four virally positive infected cell
lines (JSC–1-harboring EBV and KSHV,
BCBL–1 harboring KSHV, HeLaharboring HPV18, Cem X 174 harboring
SIV). (2) Clinical performance was
tested and validated through analysis of
total RNA from cold (swab), Japanese
Encephalitis, Dengue, Ebola and West
Nile virus samples.
Inventors: Cassio S. Baptista (NCI),
Xiaolin Wu (NCI), David J. Munroe
(NCI).
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Patent Status: U.S. Provisional
Application No 60/797,334 filed 02 May
2006 (HHS Reference No. E–206–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, PhD, MBA; 301/
435–4507; thalhamc@mail.nih.gov
Collaborative Research Opportunity:
The NCI-Laboratory of Molecular
Technology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this oligo microarray for
identification and detection of all
known mammalian and avian
pathogenic viruses. Please contact Betty
Tong, PhD at 301–594–4263 or
tongb@mail.nih.gov for more
information.
Novel Monoclonal Antibody
Microarray
Description of Technology: Gene
expression profiling at the mRNA level
has proven to be a powerful and useful
tool, however this approach suffers from
inherent limitations: (1) The mRNA
abundance does not typically correlate
well with protein abundance and (2)
protein structure, activity, and function
can be altered and regulated by posttranslational modifications. Thus, there
is growing recognition that these
approaches should be complemented by
profiles of the gene products or proteins
themselves. The present invention
provides methods for constructing and
using a novel Monoclonal Antibody
Microarray which allows highthroughput determination of protein
expression profiles from serum, tissue,
and cultured cells.
The Monoclonal Antibody Microarray
consists of more than 1000 different
antibodies immobilized on a glass slide,
which recognize antigens from several
groups of proteins, including cytokines,
kinases, apoptotic proteins, growth
factor receptors, tumor suppressors, and
oncoproteins. Protein samples to be
identified and quantified are labeled
with fluorescence and hybridized to the
antibodies immobilized on the arrays.
By differentially labeling two protein
samples (dual-color labeling) and cohybridizing to the same microarray, a
direct comparative analysis of protein
expression can be performed using as
little as 100 µg of total protein. This
method allows a large number of
samples to be screened in parallel on
identical arrays.
Applications: (1) High-throughput
analysis of protein expression; (2) Direct
measurement of protein expression at
E:\FR\FM\07SEN1.SGM
07SEN1
Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices
the gene product or post-translational
levels.
Development Status: (1) The
microarrays’ performance was tested by
proteomic profiling of two NCI–60
cancer cell lines (Renal UO–31 and
Leukemia HL–60), demonstrating a high
level of reproducibility. (2) The
microarrays’ performance was further
evaluated by analysis of the protein
expression profiles of 12 Borderline
ovarian and 9 Adenocarcinoma ovarian
tumors using normal ovarian surface
epithelial cells as a reference cell line.
It was possible to detect 77 proteins that
showed statistically significant (p<0.05)
differences distinguishing Borderline
tumors and Adenocarcinoma tumors,
demonstrating that the novel
microarrays described are useful tools
for proteomics.
Inventors: Cassio S. Baptista, Lionel
Best, David J. Munroe (NCI).
Patent Status: U.S. Provisional
Application No. 60/797,301 filed 02
May 2006 (HHS Reference No. E–207–
2006/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, PhD, MBA; 301/
435–4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The NCI-Laboratory of Molecular
Technology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this novel monoclonal
antibody microarray. Please contact
Betty Tong, PhD at 301–594–4263 or
tongb@mail.nih.gov for more
information.
Dated: August 31, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–14831 Filed 9–6–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
VerDate Aug<31>2005
18:11 Sep 06, 2006
Jkt 208001
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Methods for Enhancing Beta Cell
Function in Diabetes
Description of Technology: Diabetes
results when beta cell performance is
compromised through loss of cells or by
reduced cell function. Anti-diabetic
drugs that stimulate insulin production,
such as sulfonylureas and meglitinides,
have limited efficacy when beta cell
responsiveness is deficient. There exists
a critical need, therefore, for new
diagnostics and therapeutics that focus
on beta cell responsiveness in diabetes.
This technology describes methods
for improving pancreatic endocrine
function and delaying the onset of
diabetes by enhancing beta cell function
using ligands and/or regulators of Notch
receptors. These methods are directed
not only to mature beta cells, but to
immature beta cells and to beta cells
formed from differentiation of stem
cells. This technology also describes
isolated pancreatic progenitor cells, and
offers an effective method for
identifying and isolating these cells
using Notch receptor markers.
Applications: (1) Treatment for
diabetes that enhances beta cell function
or replaces lost beta cells; (2) Isolation
and expansion of pancreatic progenitor
cells for diabetes therapy; (3) Diagnostic
test to monitor beta cell function
Market: (1) Over 20 million people
suffer from diabetes in the United
States, and approximately 170 million
people are affected worldwide. (2) There
are an estimated 6.2 million
undiagnosed cases of diabetes in the
United States.
Development Status: Pre-clinical data
are available.
Inventors: Josephine M. Egan, et al.
(NIA).
Patent Status: U.S. Provisional
Application No. 60/590,281 filed 22 Jul
2004 (HHS Reference No. E–262–2003/
0–US–01); PCT Application No. PCT/
US2005/026207 filed 22 Jul 2005, which
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
52805
published as WO 2006/023209 on 02
Mar 2006 (HHS Reference No. E–262–
2003/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
A Nurr1-Knockout Mouse Model for
Parkinson’s Disease and Stem Cell
Differentiation
Description of Technology: The
researchers have generated Nurr1knockout mice via genomic locus
inactivation using homologous
recombination.
Transcription factor Nurr1 is an
obligatory factor for neurotransmitter
dopamine biosynthesis in ventral
midbrain. From a neurological and
clinical perspective, it suggests an
entirely new mechanism for dopamine
depletion in a region where dopamine is
known to be involved in Parkinson’s
disease. Activation of Nurr1 may be
therapeutically useful for Parkinson’s
disease patients; therefore, the mice
would be useful in Parkinson’s disease
research.
Additionally, Nurr1 has been shown
to be critical for development of
midbrain dopaminergic neurons, and
thus may contribute to stem cell-based
therapies for neurological disorders.
Nurr1 is also important for osteoblast
differentiation, suggesting a general role
in stem cell differentiation and growth.
Applications: (1) Research and drug
testing for Parkinson’s disease and other
neurological disorders; (2) Stem cell
research relating to neurological and
other disorders and bone formation.
Inventor: Dr. Vera Nikodem (NIDDK).
Relevant Publication: SO Castillo, JS
Baffi, M Palkovits, DS Goldstein, IJ
Kopin, J Witta, MA Magnuson, VM
Nikodem. Dopamine biosynthesis is
selectively abolished in substantia
nigra/ventral tegmental area but not in
hypothalamic neurons in mice with
targeted disruption of the Nurr1 gene.
Mol Cell Neurosci. 1998 May, 11(1–
2):36–46.
Related Publications:
1. MK Lee, H Choi, M Gil, VM
Nikodem. Regulation of osteoblast
differentiation by Nurr1 in MC3T3-E1
cell line and mouse calvarial
osteoblasts. J Cell Biochem. 2006 June 1
[Epub ahead of print, doi:10.1002/
jcb.20990].
2. J Jankovic, S Chen, WD Le. The role
of Nurr1 in the development of
dopaminergic neurons and Parkinson’s
disease. Prog Neurobiol. 2005 Sep-Oct,
77(1–2):128–138. Epub 2005 Oct 21,
doi:10.1016/j.pneurobio.2005.09.001.
E:\FR\FM\07SEN1.SGM
07SEN1
]]>Agencies
[Federal Register Volume 71, Number 173 (Thursday, September 7, 2006)]
[Notices]
[Pages 52804-52805]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14831]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Oligo Microarray for Detection of All Known Mammalian and Avian
Pathogenic Viruses
Description of Technology: The spectrum of pathogenic viruses of
importance in human disease, agriculture and biology is not only large
and diverse, but continually evolving. The identification or isolation
of viral pathogens, in correlation with the presence of specific
disease phenotypes, is of paramount importance both to diagnosis of
disease and the subsequent management or treatment of viral infection.
The limitations of current viral detection methods, such as PCR and
immunoassays, led to the development of a novel microarray system for
specific detection of viruses. The technology offered here for
licensing provides a method for high-throughput screening of known
pathogenic viruses along with identification of ``new'' disease-
associated viruses.
The novel method is based on a viral microarray containing 10,000
immobilized DNA oligonucleotide features, representing all known
mammalian and avian pathogenic viruses (approximately 600). Software
was also developed to analyze the viral microarray results. The
oligonucleotide features in this system are 60-mer long and distributed
across both conserved and non-conserved regions of known viral
sequences. This design serves the dual purpose of: (1) Facilitating
validation via redundant signals associated with each represented virus
and (2) allowing for the discovery of new viruses, which arise due to
recombination. In addition, positive and negative controls against
human and mouse housekeeping genes are included along with software for
analysis of virus microarray results.
Further advantages of the viral microarray include: (a) The use of
sample inputs as little as 10ng of either total DNA or RNA extracted
from virus infected cells, representing as few as 20 viral particles;
(b) detection of viruses of both DNA and RNA classes; (c) a capacity
for high-throughput screening of various sample types including serum,
saliva and biopsy tissues; and (d) analysis of a large number of
samples in parallel on identical arrays.
The detection of viral DNA is unique to this technology, as other
available technologies only detect viral genomic RNA or viral mRNA
transcripts. Additionally, the viral chip was found to be highly
specific and sensitive for detecting different viral genomic sequences
in cell lines and multiple viral constructs co-infection in cultured
cells.
Applications: (1) Detection and identification of viruses that
cause disease; (2) Efficient discovery of new pathogenic viruses; (3)
Diagnosis of human and animal disease outbreaks; (4) Identification of
viral agents used in bioterrorism.
Development Status: (1) The pre-clinical performance of the viral
microarray was evaluated by application of four virally positive
infected cell lines (JSC-1-harboring EBV and KSHV, BCBL-1 harboring
KSHV, HeLa-harboring HPV18, Cem X 174 harboring SIV). (2) Clinical
performance was tested and validated through analysis of total RNA from
cold (swab), Japanese Encephalitis, Dengue, Ebola and West Nile virus
samples.
Inventors: Cassio S. Baptista (NCI), Xiaolin Wu (NCI), David J.
Munroe (NCI).
Patent Status: U.S. Provisional Application No 60/797,334 filed 02
May 2006 (HHS Reference No. E-206-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Cristina Thalhammer-Reyero, PhD, MBA; 301/435-
4507; thalhamc@mail.nih.gov
Collaborative Research Opportunity: The NCI-Laboratory of Molecular
Technology is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize this oligo microarray for identification and detection of
all known mammalian and avian pathogenic viruses. Please contact Betty
Tong, PhD at 301-594-4263 or tongb@mail.nih.gov for more information.
Novel Monoclonal Antibody Microarray
Description of Technology: Gene expression profiling at the mRNA
level has proven to be a powerful and useful tool, however this
approach suffers from inherent limitations: (1) The mRNA abundance does
not typically correlate well with protein abundance and (2) protein
structure, activity, and function can be altered and regulated by post-
translational modifications. Thus, there is growing recognition that
these approaches should be complemented by profiles of the gene
products or proteins themselves. The present invention provides methods
for constructing and using a novel Monoclonal Antibody Microarray which
allows high-throughput determination of protein expression profiles
from serum, tissue, and cultured cells.
The Monoclonal Antibody Microarray consists of more than 1000
different antibodies immobilized on a glass slide, which recognize
antigens from several groups of proteins, including cytokines, kinases,
apoptotic proteins, growth factor receptors, tumor suppressors, and
oncoproteins. Protein samples to be identified and quantified are
labeled with fluorescence and hybridized to the antibodies immobilized
on the arrays. By differentially labeling two protein samples (dual-
color labeling) and co-hybridizing to the same microarray, a direct
comparative analysis of protein expression can be performed using as
little as 100 [mu]g of total protein. This method allows a large number
of samples to be screened in parallel on identical arrays.
Applications: (1) High-throughput analysis of protein expression;
(2) Direct measurement of protein expression at
[[Page 52805]]
the gene product or post-translational levels.
Development Status: (1) The microarrays' performance was tested by
proteomic profiling of two NCI-60 cancer cell lines (Renal UO-31 and
Leukemia HL-60), demonstrating a high level of reproducibility. (2) The
microarrays' performance was further evaluated by analysis of the
protein expression profiles of 12 Borderline ovarian and 9
Adenocarcinoma ovarian tumors using normal ovarian surface epithelial
cells as a reference cell line. It was possible to detect 77 proteins
that showed statistically significant (p<0.05) differences
distinguishing Borderline tumors and Adenocarcinoma tumors,
demonstrating that the novel microarrays described are useful tools for
proteomics.
Inventors: Cassio S. Baptista, Lionel Best, David J. Munroe (NCI).
Patent Status: U.S. Provisional Application No. 60/797,301 filed 02
May 2006 (HHS Reference No. E-207-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Cristina Thalhammer-Reyero, PhD, MBA; 301/435-
4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity: The NCI-Laboratory of Molecular
Technology is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize this novel monoclonal antibody microarray. Please contact
Betty Tong, PhD at 301-594-4263 or tongb@mail.nih.gov for more
information.
Dated: August 31, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-14831 Filed 9-6-06; 8:45 am]
BILLING CODE 4140-01-P
